Related Experiment Videos
[PPAR receptors and insulin sensitivity: new agonists in development]
1INSERM U567/CNRS UMR 8104, Institut Cochin, Département d'Endocrinologie, Université Paris V, F-75674 Paris Cedex 14, France. pegorier@cochin.inserm.fr
Annales D'Endocrinologie
|June 17, 2005
Summary
Thiazolidinediones improve glycemic control in type 2 diabetes but cause side effects. New drug classes aim to retain benefits while reducing adverse effects like weight gain and fluid retention.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Context:
- Thiazolidinediones (glitazones) are PPARgamma agonists used for type 2 diabetes.
- They improve glycemic control and insulin sensitivity, potentially protecting pancreatic beta-cells.
- Adverse effects like edema and weight gain can limit their use.
Purpose:
- To review novel pharmacological classes targeting Peroxisome Proliferator-Activated Receptors gamma (PPARgamma).
- To explore strategies for retaining beneficial metabolic effects while mitigating side effects.
- To discuss new agents including partial agonists, antagonists, dual agonists, pan agonists, and rexinoids.
Summary:
- New PPARgamma-targeting drugs are being developed to offer metabolic benefits without weight gain or fluid retention.
- These include partial PPARgamma agonists, PPARgamma antagonists, dual PPARalpha/PPARgamma agonists, pan PPARalpha/beta(delta)/gamma agonists, and RXR agonists (rexinoids).
- The review covers in vitro, animal model, and limited human studies.
Impact:
- These advancements may lead to safer and more effective treatments for type 2 diabetes.
- Future therapies could offer improved glycemic and lipid management with fewer side effects.
- This research paves the way for next-generation metabolic drugs.